Table 2.

Impact of LRRK2 variants on GCase activity.

LRRK2 variants	N of carriers	Estimate	SE	p-value*	GCase_mean	Gcase_SD
Columbia cohort
PD + controls (N=1229)
p.R1398H	204	0.521	0.233	0.026	11.960	3.804
p.M1646T	58	1.578	0.431	0.0003	12.652	4.529
p.G2019S	61	1.370	0.438	0.0018	12.798	4.340
PD (N=797)
p.R1398H	123	0.495	0.298	0.097	11.776	3.863
p.M1646T	36	1.736	0.528	0.0011	13.078	4.600
p.G2019S	57	1.440	0.450	0.0014	12.877	4.471
Controls (N=432)
p.R1398H	81	0.755	0.383	0.050	12.240	3.720
p.M1646T	22	1.367	0.746	0.068	11.956	4.425
p.G2019S	4	−0.030	1.719	0.986	11.658	1.286
PPMI cohort
PD + controls (N=470)
p.R1398H	61	−0.724	0.340	0.034	10.936	2.961
p.M1646T	23	0.295	0.543	0.587	12.717	3.510
p.G2019S	6	0.004	1.050	0.997	11.453	2.648
PD (N=326)
p.R1398H	41	−0.893	0.406	0.028	10.445	3.045
p.M1646T	17	0.073	0.623	0.907	12.385	3.259
p.G2019S	6	−0.078	1.037	0.940	11.453	2.648
Controls (N=144)
p.R1398H	20	−0.240	0.622	0.701	11.941	2.564
p.M1646T	6	1.169	1.082	0.282	13.657	4.333

SE, standard error; N, number; GCase_mean, mean glucocerebrosidase activity, μmol/l/h; SD, standard deviation; PD, Parkinson’s disease; Columbia, cohort from Columbia University, NY; PPMI, Parkinson's Progression Markers Initiative cohort

^*Bonferroni correction significance threshold for Columbia cohort (α=0.05/26=0.0019) and (α=0.05/5=0.01) for PPMI cohort.